B-cell unclassifiable lymphoma high grade

2 trials 1 recruiting MedDRA PT
2 Registered trials
1 Recruiting
2 Unique sponsors
10 Unique IMPs
0 Commercial trials
Drug classes (ATC)
H Endocrinology (ATC H) 1
L Oncology (ATC L) 2
Mechanism of action (INN-stem analysis)
CAR-T cell therapy 1 substance
Unknown / small molecule 1 substance
Platinum compound 1 substance
Antimetabolite 1 substance
Corticosteroid 1 substance
IMiD 1 substance
Antibody-drug conjugate (ADC) 1 substance
Monoclonal antibody (chimeric) 1 substance
Monoclonal antibody (rat) 1 substance
BTK inhibitor 1 substance
Phase III: 1 Phase II: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • University Of Saarland Academic
    ACALABRUTINIB
    2022-501187-18-00 2 countries 2023 n=360
    Recruiting

Phase II

1 trial
  • Instytut Hematologii I Transfuzjologii Academic
    AXICABTAGENE CILOLEUCEL; BENDAMUSTINE HYDROCHLORIDE; CISPLATIN; CYTARABINE; DEXAMETHASONE; LENALIDOMIDE; POLATUZUMAB VEDOTIN; RITUXIMAB; TAFASITAMAB
    2024-518275-64-00 1 country n=340 Orphan
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Instytut Hematologii I Transfuzjologii Academic 1 Phase II 0
University Of Saarland Academic 1 Phase III 1
New trials by year
2023
1
← All indication landscapes